Insights

Expert analysis and innovative thinking on the big issues in health analytics and life sciences.

Spotlight on our latest thinking

Pensions & benefits Health Mortality, longevity and demographic modelling Population 2050
DB schemes need to understand how trends in UK public health will impact longevity assumptions in wake of two key reports into the NHS
Press release • 27 September 2024

The findings from two recent reports into the NHS points towards a likely continuation of the modest longevity improvements seen over the 2010s and suggests that the indirect effects of the pandemic will continue to be felt over the short-medium term.
Read
Health Pensions & benefits Mortality, longevity and demographic modelling
Our reflections on NHS landmark report and what that means for longevity projections
Blog • 26 September 2024

Explore the key themes from Lord Darzi's independent review and the IPPR's report. Both reports emphasise the current scale of the challenges faced, yet most of the problems described are the culmination of mounting challenges facing the NHS in recent years.
Read
Health
LCP Health Analytics at ISPE 2024
In brief • 23 September 2024

Explore the insights we presented at ISPE 2024, the leading conference in the field of pharmacoepidemiology, on the topics of real world evidence, AI, the use of Large Language Models in drug discovery and prescription analytics.
Read
Health Life sciences
Healthcare costs surge over 60% for those with the highest obesity rates, LCP health study reveals
Press release • 20 August 2024

LCP's two studies are the first to reveal how healthcare costs increase with higher BMI and obesity levels, especially when specific obesity-related complications (ORCs) are present.
Read

A selection of external publications

Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: A retrospective open cohort study
Read on Diabetes, Obesity and Metabolism
Variations in healthcare costs by body mass index and obesity-related complications in a UK population: A retrospective open cohort study
Read on Diabetes, Obesity and Metabolism
Why is the market design for innovative pharmaceuticals not well understood?
Read on Becaris
The expanding landscape of digital health and real-world evidence in pharmacoepidemiology: reflections from ISPE 2024
Read on The Evidence Base
Weekly variation in health-care quality by day and time of admission: a nationwide, registry-based, prospective cohort study of acute stroke care
Read on The Lancet
A systematic review of machine learning models for predicting outcomes of stroke with structured data
Read on PLOS ONE
Association of Covid-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and Wales
Read on Circulation, AHA Journals
Cross-national key performance measures of the quality of acute stroke care in Western Europe
Read on Stroke, AHA Journals
The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke
Read on Sage Journals
Socioeconomic disparities in first stroke incidence, quality of care, and survival: a nationwide registry-based cohort study of 44 million adults in England
Read on The Lancet
Patient outcomes up to 15 years after stroke: survival, disability, quality of life, cognition and mental health
Read on the BMJ's Journal of Neurology, Neurosurgery & Psychiatry
Estimating the financial cost of chronic kidney disease to the NHS in England
Read on Oxford Academic
Improving health evaluations to capture wider value of therapeutics and incentivise innovation
Read on PubMed
Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence
Read on The Lancet
Excess mortality in England post Covid-19 pandemic: implications for secondary prevention
Read on The Lancet
The impact of the Covid-19 pandemic on cardiovascular disease prevention and corresponding geographical inequalities in England: interrupted time series analysis
Read on PMC
An insurance value modeling approach that captures the wider value of a novel antimicrobial to health systems, patients, and the population
Read on the Journal of Health Economics and Outcomes Research
Value-Based Healthcare in practice: IDEATE, a collaboration to design and test an outcomes-based agreement for a medicine in Wales
Read on Research Square
Emulating trials and quantifying bias: The convergence of health technology assessment agency real-world evidence guidance
Read on Value in Health
Real world outcomes, healthcare utilisation and costs of Alzheimer's disease in England
Read on ScienceDirect
Is the price right? Paying for value today to get more value tomorrow
Read on BMC Medicine
Health Technology Assessment in the US — A word of caution
Read on JAMA Internal Medicine
Does industry really develop less medicines with clinical benefit?
Read on JAMA Internal Medicine
Access in all areas? A round up of developments in market access and health technology assessment
Read Part 3 Read Part 4
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?
Read on Becaris
First in class, best in class or a wild card: who will dominate the anti-obesity medication market?
Read on Becaris
Why is target trial emulation not being used in health technology assessment real-world data submissions?
Read on Becaris
Tackling health inequalities through the development of the wider public health workforce
Read on PubMed
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment
Part 15 Part 16
A review of 25 years of National Institute of Health and Care Excellence decision making
Read on Becaris

Explore more health insights

Filter by

There are no results that match your query.

Please adjust the filters or your search term.

Get in touch

Contact us to learn more about how we can bring you clarity and insight in an increasingly complex life sciences and healthcare environment.

Insights

Spotlight on our latest thinking

DB schemes need to understand how trends in UK public health will impact longevity assumptions in wake of two key reports into the NHS

Our reflections on NHS landmark report and what that means for longevity projections

LCP Health Analytics at ISPE 2024

Healthcare costs surge over 60% for those with the highest obesity rates, LCP health study reveals

A selection of external publications

Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: A retrospective open cohort study

Variations in healthcare costs by body mass index and obesity-related complications in a UK population: A retrospective open cohort study

Why is the market design for innovative pharmaceuticals not well understood?

The expanding landscape of digital health and real-world evidence in pharmacoepidemiology: reflections from ISPE 2024

Weekly variation in health-care quality by day and time of admission: a nationwide, registry-based, prospective cohort study of acute stroke care

A systematic review of machine learning models for predicting outcomes of stroke with structured data

Association of Covid-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and Wales

Cross-national key performance measures of the quality of acute stroke care in Western Europe

The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke

Socioeconomic disparities in first stroke incidence, quality of care, and survival: a nationwide registry-based cohort study of 44 million adults in England

Patient outcomes up to 15 years after stroke: survival, disability, quality of life, cognition and mental health

Estimating the financial cost of chronic kidney disease to the NHS in England

Improving health evaluations to capture wider value of therapeutics and incentivise innovation

Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence

Excess mortality in England post Covid-19 pandemic: implications for secondary prevention

The impact of the Covid-19 pandemic on cardiovascular disease prevention and corresponding geographical inequalities in England: interrupted time series analysis

An insurance value modeling approach that captures the wider value of a novel antimicrobial to health systems, patients, and the population

Value-Based Healthcare in practice: IDEATE, a collaboration to design and test an outcomes-based agreement for a medicine in Wales

Emulating trials and quantifying bias: The convergence of health technology assessment agency real-world evidence guidance

Real world outcomes, healthcare utilisation and costs of Alzheimer's disease in England

Is the price right? Paying for value today to get more value tomorrow

Health Technology Assessment in the US — A word of caution

Does industry really develop less medicines with clinical benefit?

Access in all areas? A round up of developments in market access and health technology assessment

EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?

First in class, best in class or a wild card: who will dominate the anti-obesity medication market?

Why is target trial emulation not being used in health technology assessment real-world data submissions?

Tackling health inequalities through the development of the wider public health workforce

RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment

A review of 25 years of National Institute of Health and Care Excellence decision making

Explore more health insights

Get in touch